Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrated good glycemic efficacy in type 2 diabetes mellitus (T2DM) patients recent years [1]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.